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Abstract
Heterocyclic compounds structurally related to purine bases have been described as anticonvulsants, antifungal, antiviral, 
anticancer, enzyme inhibitors, among others. In this work, pyrazolo[3,4-d][1-3]triazin-4-ones (2) and pyrazolo[4,3-d][1-3]
triazin-4-ones (3) derivatives were evaluated as xanthine oxidase (XO) inhibitors. Compounds 3 showed the best activity 
with  IC50 values range of 0.9–2.9 µM. While the inhibition performance of pyrazolotriazinones was not more active than 
reference inhibitor allopurinol  (IC50 = 0.247 ± 0.004) µM, these nuclei provide a platform for new and more potent XO 
inhibitors. Accordingly, molecular modeling methods were carried out to understand the compounds-enzyme binding 
mode. First, we have performed a qualitative SAR study using the MOE™ SAR tool. This study showed three common 
scaffolds and the most active was identified. These results are certainly valuable and will be taken into account in future 
synthesis of structurally related compounds. Furthermore, QSAR 2D and 3D studies were performed and structural 
requirements for the activity are reported. The obtained results led us to present the structural improvements for the 
rational design and synthesis of new pyrazolotriazinone derivatives with greater xanthine oxidase inhibitory activity 
than allopurinol.
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1 Introduction
Hyperuricemia is a well-known disease produced by 
elevated levels of uric acid (UA) in the blood stream and 
it is considered as an important risk factor for the devel-
opment of gout, nephrolithiasis, cardiovascular disease, 
hypertension and diabetes. Currently, the pharmacological 
treatment is to avoid the elevated levels of UA acting in the 
purine metabolism. One of the enzymes involved in this 
process is xanthine oxidase (XO). This enzyme is widely dis-
tributed, being found in bacteria, plants and humans [1]. 
XO has a total molecular weight of 300 kDa and contains 
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a molybdenum cofactor (molybdopterin), two [2Fe–2S] 
clusters, and one FAD per subunit of the dimeric protein 
[1]. In the purine metabolism, XO oxidizes hypoxanthine 
to xanthine and this last one to uric acid (UA) [2–4]. Thus, 
human xanthine oxidase is considered a pharmacological 
target for the treatment of hyperuricemia. Allopurinol and 
febuxostat, well known inhibitors of XO, have significant 
adverse effects such as allergic reactions, skin rashes, fever, 
hepatitis, nephropathy, among others [2, 5]. Additionally, 
it has been reported that metabolites generated from the 
long-term administration of allopurinol could generate 
Stevens-Johnsons syndrome [4, 6].
Given the existing limitations in the treatment of hyper-
uricemia, there is an urgent need for discovery and devel-
opment of new XO inhibitors with less or no side effects. 
In this context, several purine analogues were reported to 
display such kind of activity, such as 9-benzoyl-9-deaza-
guanines, 9-phenyl-8-azaguanines, 8-aryl-hipoxanthines 
and 8-azaadenine [7–10].
Due to their similarity with allopurinol, we evaluate 
two series of pyrazolotriazinone (PT) compounds with 
structural similarity to purine scaffold in terms of their 
in vitro inhibitory activity of XO. Additionally, the bind-
ing mode of these compounds with the enzyme was 
determined by molecular modeling. Although PTs did 
not attain the inhibitory capacity of allopurinol, the 
activity of some derivatives was within the same range of 
this reference compound. QSAR 2D and 3D studies were 
performed in order to explain the differences between 
the behaviour of PT derivatives and also to determinate 
the structural requirements to ensure a better inhibitory 
activity. The results here obtained provide valuable infor-
mation regarding the structure–activity relationship of 
these purine-related compounds and led us to know the 
improvements necessary to synthesize, in the future, a 
new series of pyrazolotriazinone derivatives with bet-
ter inhibitory activity of XO, taking them as a valuable 
scaffold.
2  Results and discussion
2.1  Synthesis of pyrazolotriazinone (PT) 
compounds
Pyrazolo[3,4-d][1-3]triazin-4-ones (2) and pyrazolo[4,3-
d][1-3]triazin-4-ones (3) were synthesized from amino-
pyrazole-carbonitriles (1), as it is depicted in Scheme 1, 
following a diazotization protocol previously reported 
[11, 12].
2.2  In vitro XO inhibition activity
All synthesized PT compounds and allopurinol were tested 
in different concentrations in order to evaluate their inhibi-
tory activity on XO.
Every compound was active in a concentration depend-
ent manner and the  IC50 values were estimated using non-
linear fitting of concentration–response data (Table 1). In 
comparison with allopurinol  [IC50 = (0.247 ± 0.004) µM], 
the most active compounds were those corresponding to 
PTs 2, in the following descending order of activity: 2e > 
2a > 2c > 2f > 2b > 2g > 2d. According to the experimental 
results, PT derivatives 3 displayed a slightly lower activity 
than 2, except for compound 3c, which had a value of  IC50 
on the same order that 2g (Fig. 1).
Scheme 1  Synthesis 
of pyrazolo[3,4-d][1-3]
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of 2.0 Å. It was considered the best selection because 
the localization of the active site is well defined and the 
involved residues are in the 9.0 Å so here centered in 
quercetin. As site for docking was chosen a sphere of 9.0 Å 
around the co-crystallized ligand, the flavonoid quercetin. 
The docking protocol was validated by re-docking querce-
tin trying to reproduce the same position observed in the 
co-crystallized ligand (described in the “Materials and 
methods” section) (Fig. 2).
The docking study yielded binding energy values for 
allopurinol and for the most actives of each series, 2e and 
3c of − 10.42, − 8.17 and − 7.2 kcal/mol respectively, this 
being in accordance with that obtained on in vitro assays. 
The docking scores presented a good correlation with the 
bioactivity with an  r2 value of 0.76.
Regarding the docking studies taking as “site” the resi-
dues annotated in a 9.0 Å sphere centered in quercetin, 
and after the cluster analysis, three different binding sub-
sites were identified for the PT series. That result is shown 
in Fig. 3. Allopurinol, 2a, 2b, 2c, 2d, 2e and, 2f compounds 
were located into the same pocket site as quercetin, while 
2g, 3a, 3b, 3c and 3d, showed a binding site located far-
ther away, being those ligands more exposed to solvent. 
For the less active compounds, 3e and 3f, the binding site 
was in the same pocket as quercetin, but more exposed. 
Those events could explain the potency differences in the 
inhibitory activity between both families of PT derivatives.
Table 1  Xanthine oxidase inhibitory activity of pyrazolotriazinones 
derivatives
a Positive control
b Average ± SD of at least 3 determinations. p < 0.0001, the values 
resulted significantly different to allopurinol
Structure Compound R1 IC50 (μM)
b
Allopurinola H 0.247 ± 0.004
2a Ph 0.969 ± 0.004
2b p-OCH3–C6H4 1.115 ± 0.001
2c p-F-C6H4 0.97 ± 0.01
2d m-F-C6H4 2.929 ± 0.001
2e o-F-C6H4 0.907 ± 0.004
2f Pyridin-2-yl 0.980 ± 0.001
2g Benzyl 1.546 ± 0.005
3a Ph 5.715 ± 0.001
3b p-CH3–C6H4 3.96 ± 0.02
3c p-OCH3–C6H4 1.620 ± 0.001
3d p-Cl-C6H4 7.09 ± 0.04
3e p-Br-C6H4 7.83 ± 0.05
3f p-I-C6H4 8.56 ± 0.02
Fig. 1  Concentration-dependent xanthine oxidase inhibition for 
compounds 2e and 3c, and the positive reference inhibitor allopu-
rinol
Fig. 2  Crystallographic structure of quercetin in complex with XO 
(PDB ID 3NVY) (green) and, quercetin resulting of docking pose 
validation (blue)
2.3  Docking analysis
Molecular modelling studies were carried out in order to 
understand the binding mode of the two PT families and 
XO (PDB ID: 3NVY) using MOE™ 2105.10 software (“Molec-
ular Operating Environment (MOE) 2015.10”).
The PDB ID 3NVY is a crystal structure of bovine xan-
thine oxidase in complex with quercetin with a resolution 
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It has been reported that interactions with residues 
Glu802, Arg880 and Glu1261 are essential for the catalytic 
reaction [14]. Figure 4 shows a 2D graphic description of 
the ligand interactions for the most active of each series. 
For 2e, it was observed a hydrogen binding with Glu802 
residue, which was reported as essential for enzymatic 
catalysis, playing a key role in the hydroxylation of the sub-
strate [15]. For its part, 3c presented a π-cation interaction 
with Tyr1140 residue that contributed to an important 
binding affinity for this compound [15].
A correlation between the binding energy of ligands, 
estimated through the scoring functions LondondG and 
GBWSA (rescoring), make evident a correlation between 
the scored values and the biological activity (Fig. 5).
2.4  Structure activity relationship (SAR)
A qualitative SAR study was performed using the MOE SAR 
tool according to previously described [16]. The SAR proce-
dure proved the samples in three scaffolds (Fig. 6). One of 
them is those of Allopurinol (data not shown). The second 
and third scaffolds are the common substructure of PTs 2 
and PTs 3 respectively.
With reference to 2e (the most active synthesized PT 
compounds) a plot of the relative similarities and activi-
ties for all PT derivatives in the dataset, compared with 
PT 2e was performed (Fig. 7). PTs that presented higher 
activity than 2e are plotted above the vertically bisect-
ing line, while those with lower activity are plotted below. 
Only Allopurinol (that was placed above and to the right) 
resulted more active than 2e. All the rest of PT compounds 
were placed below.
The most interesting graphic information could be 
found in the two inferior quadrants. To the left of the hori-
zontal divider are plotted PT 2 compounds, which have 
the same scaffold as 2e. The distance to the left is pro-
portional to the dissimilarity of the R-group substituents 
(Fig. 6). To the right are plotted the compounds that pre-
sent different scaffolds (PTs 3). The distance between dots 
is proportional to the scaffold dissimilarity itself if both are 
assigned or the whole molecule otherwise. The similarity 
was computed using MACCS fingerprints. Allopurinol is 
located in the above right quadrant and was classified by 
the SAR as the first scaffold (data not shown).
In summary, the common scaffolds founded for PT 2 
series seems to be more prominent than that of the PT 3 
series. That information turns out to have great potential, 
and will be taken into account in future synthesis of struc-
turally related compounds.
3  2D QSAR model
Quantitative structure–activity relationship (QSAR) mod-
els are widely used to describe a biological activity with 
molecular descriptors. In this work, we have developed a 
QSAR 2D model, which allows designing and predicting 
the XO inhibitory activity of new PT derivatives in silico 
using MOE™ 2105.10. software (“Molecular Operating Envi-
ronment (MOE) 2015.10”).
Fig. 3  Binding sites of PT compounds docked to XO (3NVY). Three 
subsites were found: a Subsite 1 that includes PT 2e (detailed in 
rods); b Subsite 2 in that is shown PT 3e, c Subsite 3 in which is 
detailed in rods one of the PT compound (2g) belonging to it
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Fig. 4  Ligand interaction of 2e and 3c compounds and residues of the active site of xanthine oxidase (3NVY)
Fig. 5  Correlation between 
the docking scoring and the 
measured biological activity 
(− log (IC50)) with a resulting 
coefficient of determination 
 (R2) of 0.76
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First, several 2D molecular descriptors related to physi-
cal properties, van der Waals accessible areas, pharmaco-
phore feature descriptors, partial charge and, 3D molecu-
lar descriptors as potential energy, electronic properties, 
surface area, volume and shape, conformation depend-
ent charge descriptors, were calculated. Subsequently, 
the QSAR model was derived by partial least squares (PLS) 
method. We found that the descriptors mostly correlated 
with bioactivity were, logS [log of the aqueous solubility 
(mol/L)], AM1_IP [ionization potential (kcal/mol) calcu-
lated using the AM1 Hamiltonian (MOPAC)] and, E_sol 
[solvation energy]. The best model by PLS method showed 
a significant correlation with the bioactivity defined as 
K = − logIC50 = pIC50, with an  R
2 value of 0.85 and a root 
mean square error (RMSE) value of 0.17. The linear model 
and normalized linear model obtained are shown below:
Linear model Normalized linear model 
(SD = standard deviation)
K = 6.5878 K/SD (K) = 15.00842
− 0.612 × AM1_IP − 0.259 × AM1_IP
− 0.00846 × E_sol − 0.06930 × E_sol
 + 0.40759 × logS  + 0.78015 × logS
The linear model obtained was validated with leave-one-
out (LOO) cross-validation method. In which, a data point is 
removed from the set and the model is recalculated. Pre-
dicted activity for that point is then compared to its experi-
mental value. The correlation plot between the predicted 
and the experimental K values are displayed in Fig. 8.
From this model, it was observed that logS (log of the 
aqueous solubility), was positively correlated to K  (pIC50), 
but E_sol (solvation energy) and, AM1_IP (ionization 
potential) were negatively correlated to K. Therefore, high 
values of LogS generate higher XO inhibitory activity that 
is in accordance with the fact of low E_sol values increase 
the activity, so high hydrophilicity of molecules improves 
the XO inhibitory activity.
The high correlation observed demonstrate that the 
obtained linear model describes the bioactivity-molecular 
descriptors relationship and would be used to predict the 
XO inhibitory activity of different PT derivatives.
Fig. 6  Three scaffolds were indentified by SAR analysis where one 
of them is Allopurinol (data not shown). a The second scaffold iden-
tified inside the PTs 2, with 7 subsituents that are despicted as R2; 
b the third scaffold identified inside the PTs 3, with 6 substituents 
despicted as R1. In that scaffold a second substituent was identified 
and named as R2
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SN Applied Sciences          (2020) 2:1298  | https://doi.org/10.1007/s42452-020-2756-6 Research Article
4  3D QSAR model
CoMFA (comparative molecular field analysis) in 
Open3DQsar software was performed to study the 
correlation between the XO inhibitory activities of PT 
derivatives and, the steric and electrostatic potentials 
[17, 18]. To start with, a docking-pose conformation of 
compounds was adopted and, a rigid-body alignment of 
molecules was performed [19, 20].
In the 3D QSAR study a PLS method was used for the 
model building, and the resultant model was validated 
with LOO method for its predictive ability [19–21]. LOO 
cross-validation was used as an internal validation to 
determinate the principal components (PC) with the 
lowest RMSE and the highest cross-validated coefficient 
 q2. Both of those parameters were calculated with the 
following equations:
whereas  yi is the experimental  IC50 value of i compound, ŷi 
is the predicted  IC50 value of i compound, ȳ is the experi-
mental media of the  IC50 values of all evaluated com-
pounds [19, 20].
The statistic parameters are reported in Table 2. High  q2 
 (q2 > 0.5) value is indicate of a good predictive ability of de 
built model [20]. The model that we presented was built 
with three principal components that minimizes RMSE val-
ues and maximizes the predictive potential of  q2.
In Fig. 9, is shown the correlation plot between experi-
mental and predicted K value, with a high-predicted cor-
relation coefficient  R2 value of 0.86. This analysis revealed 





















Fig. 7  Plot of activities expressed as  IC50/µM). Color coded: green 
(values of  IC50 around 0.0001 µM), to red (values of  IC50 around 
1000 µM). Compound 2e was positioned at the center of the cross-
hairs. Other PT compounds were plotted, above or below of the 
current 2e (plot in the center), depending on whether the activ-
ity is greater or less. Compounds plotted to the left have the same 
scaffold and were in correspond to the other PT compounds of the 
series 2. PT compounds plotted to the right are those of the series 
3 and have shown a different scaffold
Vol:.(1234567890)
Research Article SN Applied Sciences          (2020) 2:1298  | https://doi.org/10.1007/s42452-020-2756-6
The steric contour maps of the CoMFA model are shown 
in Fig. 10. The yellow contours represent regions where 
bulky substituents would decrease the XO inhibitory activ-
ity, while the green contours represent regions where the 
steric bulky groups would be favorable. Those facts could 
explain the differences in the activity of each PT series, as 
it can be observed in Fig. 10a, b.
Regarding the electrostatic contours, as it is depicted in 
Fig. 11, the blue contours represent regions where neutral 
or positive charges are favorable to the activity; while in red 
regions the presence of negative charged substituents are 
promising. The most active compounds of each PT series, 
2e and 3c present, at least partially, the steric and electro-
static requirements, although this model would lead to the 
possibility of carrying out a rational design and synthesis of 
new compounds with increased activity that the PT studied 
until this point.
5  Materials and methods
5.1  Chemistry
All reagents were obtained from commercial sources and 
used without further purification. Proton (1H) and carbon 
(13C) NMR spectra were recorded on a 400 MHz Bruker 
spectrometer (1H at 400.16 MHz and 13C at 100.9 MHz) at 
ambient temperature. Solutions were typically prepared 
in either deuterochloroform  (CDCl3), deuteroacetone 
((CD3)2CO), deuterated acetonitrile  (CD3CN) or deuter-
ated dimethylsulfoxide ((CD3)2SO) with chemical shifts 
referenced to deuterated solvent as an internal standard. 
1H NMR data are reported indicating the chemical shift (δ), 
Fig. 8  Correlation plot 
between predicted vs experi-
mental K value with the QSAR 
2D model. Red point corre-
sponds to allopurinol, green 
and blue points corresponded 
to PT compounds 2 and 3 
Table 2  Statistic parameters of 
the QSAR COMFA model
q2: cross-validated correlation 
coefficient after the leave-one-
out procedure
PC principal components, 
RMSE root mean square error
PC RMSE q2
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Fig. 9  Plot of predicted versus 
experimental K value by 
CoMFA. Red point corresponds 
to allopurinol, green and blue 
points corresponded to PT 
derivatives 2 and 3 
Fig. 10  Steric contour maps for a allopurinol and the most active 
compounds of PT series 2 (2e, 2a, 2b, 2c, 2e, 2g and 2f); b allopu-
rinol and, all PT compounds. Yellow contours: regions where bulky 
substituents would decrease the XO inhibitory activity; green con-
tours: regions where the steric bulky groups would be favorable
Vol:.(1234567890)
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the multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; 
m, multiplet), the coupling constant (J) in Hz and the inte-
gration (e.g. 1H). High resolution mass spectra (HRMS) were 
recorded on a LC–MS Bruker Daltonics Micro TOFF QII with 
electrospray ionization (ESI) and Q-TOF detection.
5.2  General procedure for the synthesis of pyra-
zolotriazines
Aqueous  NaNO2 (1 mL, 1.8 mmol) was added to a stirred 
and cooled solution (0–5 °C) of pyrazole precursors (1, 1 
mmol) in a mixture of HCl:AcOH (3:1, 20 mL) over a period 
of 10 min [11, 12]. The reaction mixture was allowed to 
warm at room temperature and was stirred for 20 h. The 
precipitate of pyrazolotriazine (2 or 3) obtained was fil-
tered off, and the residue was diluted with water (20 mL). 
After that, the solution was extracted with dichlorometh-
ane (3 × 20 mL) and the organic phase was dried with anhy-
drous  MgSO4. The resulting solution was concentrated 
to dryness, and the solid was then subject to chromato-
graphic column separation with dichloromethane and 
dichloromethane/ethyl acetate in different proportions.
The spectral characteristics of compounds 2a–g corre-
sponded to literature values [11, 12].
5.2.1  7‑Phenyl‑3H‑pyrazolo[3,4‑d][1‑3]triazin‑4(7H)‑one 
(2a)
This compound was obtained as white crystals after col-
umn chromatography, 77% yield; mp 137.1 °C (dec.). 1H 
NMR (400 MHz,  CD3CN, 25 °C): δ = 7.51 (t, J = 7.0 Hz, 1 H), 
7.62 (t, J = 7.4 Hz, 2 H), 8.06 (d, J = 7.8 Hz, 1 H), 8.36 (s, 1 
H), 12.85 (s, 1H) ppm. 13C NMR (101 MHz,  CDCl3, 25 °C): 
δ = 108.1, 122.8, 128.8, 129.7, 135.4, 137.9, 147.9, 154.0. 
HRMS  (ESI+): calcd. For  C10H8N5O




This compound was obtained as an orange powder, 88% 
yield; mp 150.4 °C (dec.). 1H NMR (400 MHz,  (CD3)2SO, 
25 °C): δ= 3.85 (s, 3 H), 7.18 (d, Jorto= 9.0 Hz, 2 H), 7.92 (d, 
Jorto = 9.0 Hz, 2 H), 8.56 (s, 1 H), 15.24 (br. signal, 1H) ppm. 
13C NMR (101 MHz,  (CD3)2SO, 25 °C): δ = 55.6, 107.2, 114.6, 
124.4, 130.5, 134.9, 147.7, 153.8, 159.1 ppm. HRMS  (ESI+): 
calcd. For  C11H10N5O2
+ 244.0835; found 244.0832.
5.2.3  7‑(4‑Fluorophenyl)‑3H‑pyrazolo[3,4‑d][1‑3]tria‑
zin‑(7H)‑one (2c)
This derivative was obtained as a white power after colum-
nchromatography, 70% yield; mp 153.7 °C (dec.).1H NMR 
(400 MHz,  (CD3)2CO, 25 °C): δ = 7.43 (m, 2 H), 8.20 (m, 2 H), 
8.43 (s, 1 H), 14.02 (br. signal, 1 H) ppm. 13C NMR (101 MHz, 
 (CD3)2CO, 25 °C): δ = 108.1, 116.3, 116.5, 125.0, 125.1, 134.7, 
134.7, 135.2, 148.6, 154.2, 161.1, 163.6 ppm. HRMS  (ESI+): 
calcd. for  C10H7FN5O
+ 232.0635; found 232.0633.
5.2.4  7‑(3‑Fluorophenyl)‑3H‑pyrazolo[3,4‑d][1‑3]tria‑
zin‑4(7H)‑one (2d)
This compound was obtained as a white powder, 52% 
yield, mp 148.1 °C (dec.). 1H NMR (400 MHz,  (CD3)2SO, 25 
°C): δ = 15.39 (s, 1H), 8.65 (s, 1H,), 8.00–7.93 (m, 2H), 7.70 
(dt, J = 8.3, 6.6 Hz, 1H), 7.38 (tdd, J = 8.5, 2.5, 0.8 Hz, 1H) 
ppm. 13C NMR (101 MHz,  (CD3)2SO, 25 °C): δ = 162.1 (d, 
J = 244.5 Hz), 153.7, 148.3, 138.8 (d, J = 10.7 Hz), 135.8, 
131.5 (d, J = 9.1 Hz), 118.3 (d, J = 3.0 Hz), 115.1 (d, J = 20.9 
Hz), 109.7 (d, J = 26.6 Hz), 108.1 ppm. HRMS calculated for 
 C10H7N5OFH
+ 232.06291; found 232.06279.
5.2.5  7‑(2‑Fluorophenyl)‑3H‑pyrazolo[3,4‑d][1‑3]tria‑
zin‑4(7H)‑one (2e)
This compound was obtained as a white powder after 
column chromatography, 64% yield; mp 145.2 °C (dec.). 
1H NMR (400 MHz,  (CD3)2SO, 25 °C): δ = 7.49 (td, Jorto = 7.3 
Hz, Jmeta = 0.9 Hz, 1 H), 7.57–7.62 (m, 1 H), 7.67–7.73 (m, 1 
H), 7.79 (td, Jorto = 7.8 Hz, Jmeta = 1.7 Hz, 1 H), 8.68 (s, 1 H), 
15.32 (br. Signal, 1 H) ppm. 13C NMR (101 MHz,  (CD3)2SO, 
25 °C): δ = 106.9, 116.98 (JCβ-F = 19.5 Hz), 124.3 (JCβ-F = 11,4 
Fig. 11  Electrostatic contour maps for allopurinol and all PT deriva-
tives. Blue contours: regions where neutral or positive charges are 
favorable to the activity; red regions: negative charged substituents 
are promising to inhibitory activity
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Hz), 125.4 (JCγ-F = 4.0 Hz), 128.9, 132.1 (JCγ-F = 8.1 Hz), 136.2, 
149.0, 153.7, 155.9 (JCα-F = 252.4 Hz) ppm. HRMS  (ESI
+): 
calcd. for  C10H7N5OF
+ 232.0635; found 232.0631.
5.2.6  7‑(Pyridin‑2‑yl)‑3H‑pyrazolo[3,4‑d][1‑3]tria‑
zin‑4(7H)‑one (2f)
This compound was obtained as yellow crystals, 39% yield; 
mp 157.5 °C (dec.). 1H NMR (400 MHz,  (CD3)2SO, 25 °C): 
δ = 8.64 (ddd, J = 4.8, 1.8, 0.7 Hz, 1H), 8.49 (s, 1H), 8.14 (td, 
J = 7.6, 1.9 Hz, 1H), 7.82 (dt, J = 8.2, 0.8 Hz, 1H), 7.63 (ddd, 
J = 7.5, 4.8, 1.0 Hz, 1H) ppm. 13C NMR (101 MHz,  (CD3)2SO, 
25 °C): δ = 149.7, 148.6, 143.4, 139.9, 133.4, 125.0, 119.0, 
111.7, 94.4 ppm.
5.2.7  7‑Benzyl‑3H‑pyrazolo[3,4‑d][1‑3]triazin‑4(7H)‑one 
(2g)
The compound was obtained as colorless crystals after col-
umn chromatography, 50% yiled; mp 176.7 °C (dec.). 1H 
NMR (400 MHz,  (CD3)2SO, 25 °C): δ = 5.71 (s, 2 H), 7.33–7.48 
(m, 5 H), 8.69 (s, 1 H), 13.46 (s, 1 H) ppm. 13C NMR (101 
MHz,  (CD3)2SO, 25 °C): δ = 58.3, 107.7, 129.0, 129.3, 129.4, 
129.7, 136.5, 154.9, 158.2 ppm. HRMS (ESI +): calcd. for 
 C11H10N5O + 228.0885; found 228.0881.
5.2.8  Ethyl 4‑oxo‑6‑phenyl‑4,6‑dihydro‑3H‑pyrazolo[4,3‑d]
[1‑3]triazine‑7‑carboxylate (3a)
This compound was obtained as a pale yellow solid, 35% 
yield; mp 156.7 °C (dec). 1H NMR (400 MHz,  (CD3)2CO, 
25 °C): δ = 13.90 (s, 1H), 7.77–7.54 (m, 5H), 4.38 (q, J = 7.1 
Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (100 MHz, 
 (CD3)2CO, 25 °C): δ = 158.2, 152.9, 140.8, 137.4, 135.6, 131.0, 
130.6, 129.9, 126.8, 63.0, 14.2 ppm. HRMS calculated for 
 C13H11N5O3Na
+: 308.0754; found: 308.0760.
5.2.9  Ethyl 4‑oxo‑6‑(p‑tolyl)‑4,6‑dihy‑
dro‑3H‑pyrazolo[4,3‑d][1‑3]triazine‑7‑carboxylate 
(3b)
This compound was obtained as a yellow solid, 38% 
yield; mp 159.2 (dec). 1H NMR (400 MHz,  (CD3)2SO, 25 °C): 
δ = 14.99 (s, 1H), 7.52 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.1 Hz, 
2H), 4.33 (q, J = 7.1 Hz, 2H), 2.43 (s, 3H), 1.21 (t, J = 7.1 Hz, 
3H) ppm. 13C NMR (100 MHz,  (CD3)2SO, 25 °C): δ = 157.1, 
152.3, 140.1, 137.0, 136.1, 134.0, 129.4, 128.8, 125.7, 62.1, 
20.8, 13.8 ppm. HRMS calculated for  C14H13N5O3Na
+: 
322.0911; found: 322.0906.
5.2.10  Ethyl 6‑(4‑methoxyphenyl)‑4‑oxo‑4,6‑dihy‑
dro‑3H‑pyrazolo[4,3‑d][1‑3]triazine‑7‑carboxylate 
(3c)
This compound was obtained as a light brown solid, 28% 
yield; mp 164.3 °C (dec). 1H NMR (400 MHz,  CDCl3, 25 °C): 
δ = 11.55 (s, 1H), 7.47 (d, J = 8.9 Hz, 2H), 7.03 (d, J = 8.9 Hz, 
2H), 4.47 (q, J = 7.1 Hz, 2H), 3.90 (s, 3H), 1.37 (t, J = 7.1 Hz, 
3H) ppm. 13C NMR (101 MHz,  CDCl3, 25 °C): δ = 161.2, 158.8, 
157.7, 151.9, 134.4, 132.2, 127.1, 114.3, 109.9, 63.0, 55.8, 
29.9 ppm. HRMS calculated for  C14H13N5O4Na
+: 338.0806; 
found: 338.0863.
5.2.11  Ethyl 6‑(4‑chlorophenyl)‑4‑oxo‑4,6‑dihy‑
dro‑3H‑pyrazolo[4,3‑d][1‑3]triazine‑7‑carboxylate 
(3e)
This compound was obtained as a pale yellow solid, 
31% yield; mp 172.1 (dec). 1H NMR (400 MHz,  CD3CN, 
25 °C): δ = 12.70 (s, 1H), 7.59 (m, 4H), 4.38 (q, J = 7.1 
Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (101 MHz, 
 CD3CN, 25 °C): δ = 158.3, 153.1, 139.4, 137.6, 136.7, 135.8, 
130.8, 130.1, 128.7, 63.6, 14.2 ppm. HRMS calculated for 
 C13H10ClN5O3Na
+: 342.0364; found: 342.0374.
5.2.12  Ethyl 6‑(4‑bromophenyl)‑4‑oxo‑4,6‑dihy‑
dro‑3H‑pyrazolo[4,3‑d][1‑3]triazine‑7‑carboxylate 
(3f)
This compound was obtained as a yellow solid, 36% yield; 
mp 175.8 °C (dec). 1H NMR (400 MHz,  (CD3)2CO, 25 °C): 
δ = 13.93 (s, 1H), 7.83 (d, J = 8.8 Hz, 2H), 7.67 (d, J = 8.8 Hz, 
2H), 4.41 (q, J = 7.1 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H) ppm. 13C 
NMR (101 MHz,  (CD3)2CO, 25 °C): δ = 158.2, 152.8, 140.0, 
137.4, 135.8, 133.0, 130.6, 129.0, 124.6, 63.1, 14.3 ppm. 
HRMS calculated for  C13H10BrN5O3Na
+: 385.9859; found: 
385.9868.
5.2.13  Ethyl 6‑(4‑iodophenyl)‑4‑oxo‑4,6‑dihy‑
dro‑3H‑pyrazolo[4,3‑d][1‑3]triazine‑7‑carboxylate 
(3g)
This compound was obtained as a yellow solid, 33% 
yield; mp 178.9 (dec.). 1H NMR (400 MHz,  (CD3)2CO, 25 °C): 
δ = 13.90 (s, 1H), 7.77–7.54 (m, 4H), 4.38 (q, J = 7.1 Hz, 2H), 
1.27 (t, J = 7.1 Hz, 3H) ppm. 13C NMR (101 MHz,  (CD3)2CO, 25 
°C): δ = 158.2, 152.8, 140.7, 139.1, 137.4, 135.8, 130.6, 128.9, 
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5.3  Xanthine oxidase inhibitory activity
The assay was performed as previously described by Santi 
et al. [14]. Briefly, the assay medium consisting of 21.4 µL 
of xanthine oxidase solution from bovine milk (0.04 U/mL, 
Sigma Chemical Co., St Louis, MO, USA), and 0.75 mL of the 
control solution  [K2HPO4/KH2PO4 buffer (0.07 M, pH 7.5)] or 
the sample solution (prepared with each compound dis-
solved in DMSO and subsequently diluted to the appro-
priate concentrations with the above buffer) were mixed 
and pre-incubated at 25 °C for 15 min. Then, 0.45 mL of 
the xanthine solution substrate (150 µM, Sigma Chemical 
Co., St Louis, MO, USA) was added and pre-incubated at 
25 °C for 30 min. The reaction was then stopped by the 
addition of 1 mL of HCl (1 N) and the absorbance was 
measured at 290 nm on a Cary Win UV–VIS spectropho-
tometer, Varian, Inc., Agilent Technologies (Santa Clara, 
USA). Allopurinol (Sigma Chemical Co., St Louis, MO, 
USA) was used as positive inhibitor control. Each treat-
ment was replicated three times. The percent inhibition 
of xanthine oxidase activity was calculated as follows: % 
inhibition = [(Abscontrol − Abssample)/Abscontrol] × 100, where 
 Abscontrol is the absorbance of the control solution and 
 Abssample is the absorbance of the sample solution.
5.4  Calculations and statistics
All assays were independently performed in triplicate, 
and results were expressed as media ± SD of three sepa-
rate experiments. The  IC50 values were estimated using 
the OriginPro 8.0 software on a compatible computer. The 
results were analyzed by unidirectional analysis of variance 
(ANOVA) followed by the Bonferroni’s test for multiple 
comparisons using GraphPad Prism 6.0 software.
5.5  Ligands preparation
The 3D structures of all PT compounds were built and 
minimized in MOE™ 2105.10. using the MMFF94x force-
field. A conformational search was carried out through the 
LowModeMD conformational search module [13, 22–24].
5.6  Protein preparation
The crystal structure from milk bovine xanthine oxidase 
in complex with quercetin (PDB ID = 3NVY) at 2.0 resolu-
tion was obtained from Protein Data Bank (http://www.
rcsb.org/pdb) [25]. All water molecules were deleted, and 
charges and hydrogens atoms were adjusted with the 
Amber10 forcefield from MOE™ 2105.10 [13].
5.7  Docking studies
Docking studies were performed on MOE software, con-
sidering all residues in a sphere of 9 Å centered on the 
co-crystallized ligand in the C chain. Proxy Triangle was set 
as placement function. First scoring was calculated with 
London dG function, followed by pose refinement and 
re-scoring with GBVI/WSA dG method. Both algorithms 
are presented in the Equ. 1SP in the supplementary mate-
rial. Electrostatic was considered in different aspects. For 
one hand the used force field (MMFF94x) evaluates the 
electrostatic interaction by means of Coulomb equation 
(Eq. 1SP). Partial charges are assessed in the case of ligands 
(phenols) and an example is shown in the Fig. 1SP of Supp. 
Mat. On the other hand, the scoring used by the docking 
process included an evaluation by London dG and GBVI/
WSA dG algorithms above mentioned and an assessment 
of partial charges given in the same way by the force field. 
A validation procedure reproducing the same pose of 
quercetin in the crystal structure with our method with a 
RMSD value of 0.387 was executed.
5.8  Structure activity relationship (SAR)
A qualitative SAR study was performed using the MOE SAR 
tool that provides a report (web page) housing an inter-
active view onto the data set of pyrazolotriazinones. The 
structure–activity report is a MOE application, which gen-
erates a web page housing an interactive view onto our 
collection of molecules. The online report contains a num-
ber of tabs for examining the common scaffolds, R-groups, 
structure vs. activity, fragmentation and, various graphs 
and interactive widgets. Clark and Labute [16] describes 
the algorithm used to detect and analyze scaffolds.
6  2D QSAR model
A data base of thirteen PT derivatives was used for the 
QSAR study using MOE software. The  IC50 values were 
converted to negative logarithmic (K = plogIC50). Differ-
ent types of descriptors and their correlation matrix were 
calculated. A lineal model was built with PLS method with 
three non-collinear descriptors, all of them associates with 
XO inhibitory activity.
7  3D QSAR model
A rigid body alignment of PT compounds database was 
used in Open3DQsar software to carry out a Comparative 
molecular field analysis (CoMFA), relating the molecular 
interaction of steric and electrostatic fields with bioactivity. 
Vol.:(0123456789)
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A 0.5 Å grid for molecular interaction fields calculations 
was built. The CoMFA steric fields were calculated using 
the sp3 carbon as the probe atom, following the standard 
proceed of MMFF94 force field. On the other hand, the 
CoMFA electrostatic fields were calculated with the quan-
tum mechanics Ab initio method with a Hartree–Fock level 
of theory with 6–311** functions on Gamess software (ver-
sion September 30, 2018 R3 for 64 bit) [26]. The steric and 
electrostatic energy cutoff was set to 30 kcal/mol and, low 
variability points (standard deviation < 0.1) were deleted.
A normalization of the relative importance of both 
fields was performed using the Block Unscaled Weighting 
(BUW) tool [27].
The validation procedure of 3D-QSAR model was 
realized with a partial least square (PLS) analysis. Leave-
one-out (LOO) method was used to calculate the cross-
validated  (q2) value and the number of the principal com-
ponents (PC). Finally, that model was improved using the 
Smart region definition (SRD) method [28]. This procedure 
reduces redundancy arising from the existence of multiple 
nearby descriptors, which basically encode the same kind 
of information.
8  Conclusions
Given the absence of drugs without prejudicial adverse 
effects to gout disease treatment, the search for therapeu-
tic alternatives is very important.
In this work, we reported the in vitro XO inhibitory 
activity of thirteen pyrazolotriazinones derivatives. All 
compounds were active on XO however; none presented 
an inhibitory activity greater than allopurinol. Consider-
ing these results, we proceeded to conduct in silico stud-
ies. Those studies allowed us to understand the binding 
mode PT compounds-XO. Additionally, we present a SAR 
study and, 2D and 3D QSAR models that describe the 
observed behavior and provide valuable information for 
the rational design and synthesis of new PT derivatives 
with an improved XO inhibitory activity. Thus, we present 
here a series of purine analogues as scaffolds for obtaining 
therapeutic alternative compounds for the of gout disease 
treatment.
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